WO2023059118A1 - Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré - Google Patents

Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré Download PDF

Info

Publication number
WO2023059118A1
WO2023059118A1 PCT/KR2022/015081 KR2022015081W WO2023059118A1 WO 2023059118 A1 WO2023059118 A1 WO 2023059118A1 KR 2022015081 W KR2022015081 W KR 2022015081W WO 2023059118 A1 WO2023059118 A1 WO 2023059118A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
coating layer
weight
salt
alogliptin
Prior art date
Application number
PCT/KR2022/015081
Other languages
English (en)
Korean (ko)
Inventor
권시안
박단비
이병훈
조우형
조은주
문성국
한성균
홍언표
Original Assignee
(주)셀트리온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)셀트리온 filed Critical (주)셀트리온
Publication of WO2023059118A1 publication Critical patent/WO2023059118A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a pharmaceutical composition for the treatment of diabetes with improved stability, and more particularly, to a pharmaceutical composition comprising a core containing metformin or a salt thereof and a drug coating layer containing alogliptin or a salt thereof, including a barrier coating layer therebetween It relates to a pharmaceutical composition with improved stability deterioration due to contact between two components.
  • DPP-IV dipeptidyl peptidase IV
  • Alogliptin is widely used as a treatment for type 2 diabetes, and diabetes is not properly controlled with metformin alone. It can be used in combination with metformin in patients with
  • Korean Patent No. 1536786 includes a first part containing alogliptin or a salt thereof and substantially free of metformin hydrochloride, and a second part containing metformin hydrochloride and substantially free of alogliptin and its salt.
  • a formulation is disclosed.
  • the stability of alogliptin may be deteriorated due to the contact between the components at the interface between the first and second parts of the formulation, and when a sustained-release agent is included in the first part including metformin hydrochloride, the dissolution of alogliptin is delayed. this can happen
  • the inventors of the present invention further include a barrier layer between a core containing metformin or a salt thereof and a coating layer containing alogliptin or a salt thereof to confirm that dissolution and stability degradation problems are improved. has been completed.
  • the problem to be solved by the present invention is to provide a pharmaceutical composition for the treatment of diabetes with improved stability that prevents deterioration in stability due to contact between two components at the interface and at the same time prevents the delay in dissolution of alogliptin by metformin sustained-release agent. .
  • the present inventors conducted various studies to improve stability by preventing contact between the two components, and as a result, a pharmaceutical composition with excellent stability including a barrier coating layer and a drug coating layer to which a coating agent with excellent compatibility with alogliptin and metformin was applied
  • the present invention was completed by producing.
  • a core comprising metformin or a salt thereof; (2) a barrier coating layer coated on the core; and (3) a drug coating layer coated on the barrier coating layer and containing alogliptin or a salt thereof, wherein the drug coating layer contains 50 to 200 polyvinyl alcohol by weight of alogliptin or a salt thereof.
  • a pharmaceutical composition comprising % by weight is disclosed.
  • the core may be an uncoated tablet containing metformin or an optically active form thereof or a salt thereof.
  • the salt is a pharmaceutically acceptable salt that can be commonly used in the art, and for example, hydrochloride salts, magnesium salts, strontium salts, lithium salts, sodium salts, potassium salts, calcium salts, etc. may be used, but are limited thereto it is not going to be
  • the core may contain 250 to 1500 mg, preferably 500 to 1250 mg of metformin or a salt thereof.
  • the core may be 80 to 97% by weight based on the total weight of the pharmaceutical composition.
  • the pharmaceutical composition according to one embodiment of the present invention may include a sustained-release agent in the core for a sustained-release effect of metformin or a salt thereof.
  • the sustained-release agent is hydroxypropyl cellulose, methyl cellulose, carrageenan, glyceryl behenate, hydrogenated castor oil, hydrogenated vegetable oil, stearic acid, polyvinyl acetate, polyvinyl alcohol, povidone, polyethylene glycol, hydrogel Roxyethyl cellulose, hypromellose, polyethylene oxide, sodium carboxymethyl cellulose, carbomer, sodium alginate, or mixtures thereof may be used.
  • sustained-release agents include Eudragit RS100, RSPO, RS30D, RL100, RLPO, RL30D, NE30D, NE40D (Rohm Pharma), Kollidon SR, Kollicoat ( Kollicoat) SR30D, etc., and one or more selected from them may be used.
  • the sustained-release agent may be included in 5 to 50% by weight, preferably 10 to 35% by weight, based on the weight of the core.
  • the barrier coating layer and the drug coating layer may be coated with a coating agent containing a coating polymer and a coating adjuvant.
  • the pharmaceutical composition according to one embodiment of the present invention may include a barrier coating layer and a drug coating layer using a coating polymer having excellent compoundability.
  • the coating polymer in the coating agent is polyvinyl alcohol (PVA), hydroxypropyl cellulose (HPC), hypromellose (HPMC), polyvinyl alcohol-polyethylene glycol copolymer (PVA-PEG copolymer ), hydroxypropyl starch, dimethylaminoethyl methacrylate ⁇ methyl methacrylate copolymer, ethyl methacrylate -chlorotrimethylammonium methacrylate copolymer, methacrylic acid ⁇ ethyl acrylate copolymer, hypromellose acetate succinate and hypro It may be mellose phthalate or a mixture thereof.
  • the drug coating layer may have excellent drug safety effects by including polyvinyl alcohol as a coating polymer.
  • examples of products of the coating agent include 85A 680001 White, 85A 620000 Yellow, 85A 620007 Yellow, 85A620015 Yellow, 20A 28381 White, 88A 180040 White, etc., including polyvinyl alcohol, and polyvinyl alcohol-polyethylene It may be 321A 180025 White in which Kollicoat IR including a glycol copolymer is used, and one or more selected from these may be used, but is not limited thereto.
  • the barrier coating layer may be included in 1 to 8% by weight, preferably 1.5 to 6% by weight, more preferably 2 to 4% by weight, based on the total weight of the pharmaceutical composition.
  • the barrier coating layer may be included in 1 to 6% by weight, preferably 2 to 5% by weight, more preferably 2.5 to 4% by weight, based on the weight of the core.
  • the barrier coating layer is polyvinyl alcohol, hydroxypropyl cellulose, hypromellose, polyvinyl alcohol-polyethylene glycol copolymer, hydroxypropyl starch, dimethylaminoethyl methacrylate as a coating polymer.
  • It may include methyl acrylate copolymer, ethyl methacrylate-chlorotrimethylammonium ethyl methacrylate copolymer, methacrylic acid/ethyl acrylate copolymer, hypromellose acetate succinate and hypromellose phthalate, or mixtures thereof, preferably Preferably, it may include polyvinyl alcohol, hydroxypropyl cellulose, hypromellose, or polyvinyl alcohol-polyethylene glycol copolymer.
  • the barrier coating layer may include 30 to 200% by weight, preferably 40 to 180% by weight, more preferably 50% by weight of the coating polymer relative to the weight of alogliptin or a salt thereof in the drug coating layer. to 170% by weight.
  • the barrier coating layer may include 5 to 40 mg of the coating polymer, preferably 7 to 35 mg, and more preferably 10 to 30 mg.
  • the barrier coating layer may contain 15 to 100% by weight of the coating polymer, preferably 25 to 80% by weight, more preferably 35 to 65% by weight, based on the total weight of the barrier coating layer.
  • the barrier coating layer may include talc, titanium oxide, pigment, etc. as a coating aid.
  • the drug coating layer may be a coating layer containing alogliptin or an optically active form thereof or a salt thereof.
  • the salt is a pharmaceutically acceptable salt that can be commonly used in the art, and for example, a metal salt or ammonium salt such as benzoate, magnesium salt, strontium salt, lithium salt, sodium salt, potassium salt, calcium salt may be used. It can, but is not limited thereto.
  • the drug coating layer may include 1 to 100 mg, preferably 5 to 60 mg, and more preferably 10 to 40 mg of alogliptin or a salt thereof.
  • the drug coating layer may be included in 1 to 15% by weight, preferably 2 to 10% by weight, more preferably 2.5 to 9% by weight, based on the total weight of the pharmaceutical composition.
  • the drug coating layer may include 50 to 200% by weight of polyvinyl alcohol, preferably 80 to 170% by weight, more preferably 100 to 140% by weight based on the weight of alogliptin or a salt thereof. % can be included.
  • the drug coating layer may include 5 to 100 mg of polyvinyl alcohol, preferably 10 to 80 mg, and more preferably 15 to 50 mg.
  • the drug coating layer may further include hydroxypropyl cellulose.
  • Hydroxypropylcellulose may be included in an amount of 0.01 to 80% by weight, preferably 5 to 60% by weight, and more preferably 10 to 55% by weight, based on the weight of alogliptin or a salt thereof.
  • Hydroxypropylcellulose may contain 0.01 to 16 mg, preferably 0.1 to 13 mg, and more preferably 1 to 10 mg.
  • the drug coating layer may include polyvinyl alcohol and hydroxypropyl cellulose at a ratio of 10:1 to 1:1, preferably at a ratio of 9:1 to 4:1.
  • the drug coating layer may contain 10 to 65% by weight of polyvinyl alcohol, preferably 20 to 50% by weight, more preferably 30 to 40% by weight, based on the total weight of the drug coating layer.
  • the drug coating layer may include 0.01 to 30% by weight of hydroxypropylcellulose, preferably 0.1 to 25% by weight, more preferably 2 to 10% by weight, based on the total weight of the drug coating layer. can do.
  • the drug coating layer may include talc, titanium oxide, pigment, etc. as a coating aid.
  • the core; barrier coating layer; And a pharmaceutical composition may be prepared including a drug coating layer.
  • the pharmaceutical composition may further include a pharmaceutically acceptable disintegrant, for example, croscamellose sodium, sodium starch glycolate, pregelatinized Starch (Pregelatinized Starch) [Starch 1500 or Prejel], microcrystalline cellulose, crospovidone, cross-linked povidone, low substituted hydroxypropylcellulose, alginic acid, Carboxymethylcellulose calcium salt or sodium salt, colloidal silica collidal silica, guar gum, magnesium aluminum silicate, methylcellulose, powdery cellulose, It may be one or a mixture of two or more selected from the group consisting of starch and sodium alginate.
  • a pharmaceutically acceptable disintegrant for example, croscamellose sodium, sodium starch glycolate, pregelatinized Starch (Pregelatinized Starch) [Starch 1500 or Prejel], microcrystalline cellulose, crospovidone, cross-linked povidone, low substituted hydroxypropylcellulose, alginic acid, Carboxymethylcellulose calcium salt or sodium salt,
  • the pharmaceutical composition may include additives such as pharmaceutically acceptable excipients, binders, and lubricants.
  • additives such as pharmaceutically acceptable excipients, binders and lubricants are lactose, dextrin, mannitol, sorbitol, starch, calcium phosphate, microcrystalline cellulose, hydroxypropyl cellulose, povidone, polyvinyl alcohol, colloidal It may be silicon dioxide, stearic acid, glyceryl behenate, hydrogenated vegetable oil, hydrogenated castor oil, magnesium stearate, and talc, but is not limited thereto.
  • the pharmaceutical composition may be a tablet, capsule or granule, preferably a tablet.
  • the pharmaceutical composition may be further coated.
  • the pharmaceutical composition according to the present invention may have a stability improvement effect by including a barrier coating layer and a drug coating layer to which a coating agent having excellent compatibility with alogliptin and metformin is applied.
  • an improved dissolution effect can be expected by preventing the delayed dissolution of alogliptin by the sustained-release agent of the metformin-containing core.
  • FIG. 1 is a schematic diagram showing the structure of a pharmaceutical composition with improved stability according to the present invention.
  • 2 to 4 are graphs measuring tablet stability according to coating agent components and contents.
  • a barrier coating solution for forming a barrier coating layer surrounding a metformin-containing core was prepared using the components and contents of the coating agent shown in Table 1.
  • a barrier coating solution was prepared by adding the components and contents of the coating agent in Table 1 to purified water and stirring, and then spraying it onto the uncoated tablet prepared in the above step to form a barrier coating layer.
  • a drug coating solution was prepared with the main component (alogliptin benzoate) and coating agents shown in Table 1. After dispersing the main component in purified water with an agitator and homogenizing with a homogenizer, a coating solution is prepared by mixing the coating agent in the dispersed solution, and the prepared barrier coating tablet is put into a coating machine, then the drug coating solution is sprayed and dried. Drug-coated tablets were prepared.
  • Comparative Example 1 Comparative Example 2
  • Example 1 Example 2
  • Example 3 Uncoated tablet with metformin 1390 1390 1390 1390 1390 barrier coating layer Polymer for coating PVA - - 21 22 22 HPC 13 42 - 6 3 HPMC 13 - - - - coating aid Talc, TiO2, pigment 16 2 26 18 21 drug coating layer API Alogliptin benzoate 17 17 17 17 17 Polymer for coating PVA - - 21 22 22 HPC 10 34 - 6 3 HPMC 10 - - - - coating aid Talc, TiO2, pigment 14 2 26 20 22 Total 1483 1487 1501 1501 1500
  • TiO 2 may be included as coating aids
  • Nesina tablets 17 mg of alogliptin benzoate, a commercial product, was used as a control drug.
  • the RRT Relative retention time
  • 1.2 and 1.22 peak positions which show a marked increase in related substances compared to the peak position of the main component, were quantified to determine tablet stability according to the components and contents of the coating agent. The improvement effect was confirmed.
  • the coated tablets prepared in Comparative Examples and Examples were packed in a sealed vial and an aluminum bag (Al-bag) with a rubber seal at 50 ° C and 75% relative humidity, and an increase in related substances was confirmed after 2 weeks of storage.
  • the barrier coating layer was prepared in the same manner as in Example 1, except that the barrier coating layer was prepared as shown in Table 3 below.
  • Example 4 Example 5 Example 6 barrier coating layer Polymer for coating HPC - 28 - PVA-PEG 28 - - HPMC - - 28 coating aid Talc, TiO 2 , pigment 18 18 18
  • the related substances of the tablets of Examples 1 and 4 to 6 were analyzed, and the RRT (Relative retention time) 1.22 peak position, which showed a marked increase in related substances compared to the peak position of the main component, was quantified to confirm the effect of improving tablet stability according to the components and contents of the coating agent.
  • the coated tablet prepared in Example was packed in a sealed bottle and an aluminum bag at 50 ° C and 75% relative humidity, and an increase in related substances was confirmed after 4 weeks of storage.

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement du diabète sucré, avec une stabilité améliorée et, plus spécifiquement, une composition pharmaceutique comprenant un noyau contenant de la metformine ou un sel de celle-ci, une couche d'enrobage de médicament contenant de l'alogliptine ou un sel de celle-ci, et une couche d'enrobage de protection entre les deux, grâce à quoi le problème de la réduction de la stabilité attribuée au contact entre les deux ingrédients est résolu.
PCT/KR2022/015081 2021-10-08 2022-10-07 Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré WO2023059118A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210134415 2021-10-08
KR10-2021-0134415 2021-10-08

Publications (1)

Publication Number Publication Date
WO2023059118A1 true WO2023059118A1 (fr) 2023-04-13

Family

ID=85804537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/015081 WO2023059118A1 (fr) 2021-10-08 2022-10-07 Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré

Country Status (3)

Country Link
KR (1) KR20230051096A (fr)
TW (1) TW202329921A (fr)
WO (1) WO2023059118A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100036367A (ko) * 2007-07-19 2010-04-07 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
KR20110005690A (ko) * 2008-04-03 2011-01-18 베링거 인겔하임 인터내셔날 게엠베하 추가의 항당뇨병제와 병용된 ｄｐｐ-ｉｖ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법
KR20130137624A (ko) * 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
WO2016105084A2 (fr) * 2014-12-23 2016-06-30 주식회사 한독 Composition pharmaceutique pour le traitement du diabète
WO2020242413A1 (fr) * 2019-05-24 2020-12-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinaison comprenant de l'alogliptine et de la metformine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020098904A1 (fr) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Forme posologique contenant de la metformine et un inhibiteur de la dipeptidyl peptidase iv

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100036367A (ko) * 2007-07-19 2010-04-07 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
KR20110005690A (ko) * 2008-04-03 2011-01-18 베링거 인겔하임 인터내셔날 게엠베하 추가의 항당뇨병제와 병용된 ｄｐｐ-ｉｖ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법
KR20130137624A (ko) * 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
WO2016105084A2 (fr) * 2014-12-23 2016-06-30 주식회사 한독 Composition pharmaceutique pour le traitement du diabète
WO2020242413A1 (fr) * 2019-05-24 2020-12-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinaison comprenant de l'alogliptine et de la metformine

Also Published As

Publication number Publication date
TW202329921A (zh) 2023-08-01
KR20230051096A (ko) 2023-04-17

Similar Documents

Publication Publication Date Title
EP2830618A1 (fr) Composition pharmaceutique comprenant de l'olmésartan médoxomil et de la rosuvastatine ou son sel
WO2015093796A1 (fr) Comprimés pelliculés contenant de l'alfoscérate de choline et procédé pour les préparer
WO2019147094A1 (fr) Formulation pharmaceutique comprenant de l'ésoméprazole et du bicarbonate de sodium
WO2013133620A1 (fr) Composition pharmaceutique comprenant du clopidogrel et de l'aspirine et son procédé de préparation
WO2012148181A2 (fr) Composition à libération contrôlée de médicaments
WO2023059118A1 (fr) Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré
WO2019066555A1 (fr) Composition pharmaceutique comprenant un comprimé sphéroïdal à unités multiples contenant de l'ésoméprazole et un sel de qualité pharmaceutique de celui-ci, et procédé de préparation de la composition pharmaceutique
WO2015108392A1 (fr) Petit comprimé pharmaceutique contenant de l'ésoméprazole
WO2020106007A1 (fr) Comprimé pelliculé ayant une excellente propriété d'étanchéité à l'humidité
WO2013157841A1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
WO2015102337A1 (fr) Composition pharmaceutique contenant de la clomipramine et son procédé de préparation
WO2021221288A1 (fr) Association médicamenteuse comprenant du mosapride et un inhibiteur de la pompe à protons
WO2021118026A1 (fr) Formulation de comprimé à noyau contenant un inhibiteur de la pompe à protons et du mosapride
WO2021157883A1 (fr) Agent de capsule dure comprenant un inhibiteur entérique de pompe à protons et une formulation de mosapride à libération prolongée
WO2021112548A1 (fr) Composition pharmaceutique
WO2020080875A1 (fr) Composition orale contenant de l'aprépitant
WO2019199134A1 (fr) Composition pharmaceutique comprenant du lénalidomide
WO2016175546A2 (fr) Composition pharmaceutique à libération prolongée contenant de la rivastigmine
WO2016144071A2 (fr) Formulations pharmaceutiques comprenant du rivaroxaban
WO2018203636A1 (fr) Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées
WO2013095042A2 (fr) Granulé contenant du mésylate d'imatinib, composition pour comprimé à libération immédiate administré par voie orale contenant le granulé, et méthode de préparation associée
WO2021080184A1 (fr) Composition pharmaceutique de petite taille et à libération prolongée comprenant de l'alfoscérate de choline
WO2022039478A1 (fr) Procédé de préparation d'une composition de diltiazem à libération prolongée en comprimé par auto-granulation
CA2457385A1 (fr) Preparation enterique de fluoxetine
WO2023282698A1 (fr) Formulation à libération immédiate contenant du ténofovir alafénamide présentant une stabilité de formulation améliorée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22878939

Country of ref document: EP

Kind code of ref document: A1